Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 144 citing articles:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 332
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 303
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 229
Challenges and opportunities in NASH drug development
Stephen A. Harrison, Alina M. Allen, Julie Dubourg, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 562-573
Closed Access | Times Cited: 199
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 165
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei‐Chuan Lee, Pei-Shan Wu, Han‐Chieh Lin
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 1, pp. 77-98
Open Access | Times Cited: 113
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Xiumei Wu, Mengyun Xu, M. Geng, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 99
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 888-897
Open Access | Times Cited: 97
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Julian M. Yabut, Daniel J. Drucker
Endocrine Reviews (2022) Vol. 44, Iss. 1, pp. 14-32
Open Access | Times Cited: 75
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 2, pp. 179-191
Open Access | Times Cited: 75
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
Paloma Sangro, Manuel de la Torre‐Aláez, Bruno Sangro, et al.
Journal of Physiology and Biochemistry (2023) Vol. 79, Iss. 4, pp. 869-879
Open Access | Times Cited: 67
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai–Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 62
NAFLD and NASH: etiology, targets and emerging therapies
Shulin Wei, Li Wang, Paul C. Evans, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103910-103910
Closed Access | Times Cited: 57
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 56
FXR agonists in NASH treatment
Luciano Adorini, Michael Trauner
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1317-1331
Open Access | Times Cited: 54
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Paul Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 679-688
Open Access | Times Cited: 50
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
William P. Esler, David E. Cohen
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 362-377
Open Access | Times Cited: 45
SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors
Qin Sun, Xiaorui Xing, Huanyu Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115586-115586
Open Access | Times Cited: 45
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Monica A. Tincopa, Quentin M. Anstee, Rohit Loomba
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 912-926
Closed Access | Times Cited: 35
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 35
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Stephen A. Harrison, Sarah K. Browne, John J. Suschak, et al.
Journal of Hepatology (2024)
Open Access | Times Cited: 32
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 31
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 23
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5640-5640
Open Access | Times Cited: 21
MASH clinical trials and drugs pipeline: An impending tsunami
Mazen Noureddin
Hepatology (2024)
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top